BioMarin Pharmaceuticals
BMRN
547 hedge funds and large institutions have $18B invested in BioMarin Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 85 funds opening new positions, 178 increasing their positions, 207 reducing their positions, and 50 closing their positions.
70% more first-time investments, than exits
New positions opened: 85 | Existing positions closed: 50
36% more call options, than puts
Call options by funds: $193M | Put options by funds: $141M
12% more capital invested
Capital invested by funds: $16.1B → $18B (+$1.96B)
5% more funds holding
Funds holding: 519 → 547 (+28)
2.79% more ownership
Funds ownership: 96.45% → 99.24% (+2.8%)
0% more funds holding in top 10
Funds holding in top 10: 14 → 14 (0)
14% less repeat investments, than reductions
Existing positions increased: 178 | Existing positions reduced: 207
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$421M |
| 2 |
EIM
Elliott Investment Management
West Palm Beach,
Florida
|
+$265M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$177M |
| 4 |
Morgan Stanley
New York
|
+$99M |
| 5 |
Millennium Management
New York
|
+$80M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$337M |
| 2 |
Nomura Holdings
Tokyo,
Japan
|
-$62.6M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$56.1M |
| 4 |
Pictet Asset Management
Carouge,
Switzerland
|
-$44.7M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$44.1M |
BMRN Hedge Fund Activity: Q4 2023 in Review
547 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q4 2023, worth a combined $18B — up 12% from $16.1B a quarter earlier.
Buyers outnumbered sellers: 85 funds opened new BMRN positions and 50 closed out — a net gain of 35 holders — while 178 added to existing stakes and 207 trimmed.
The largest buyer was Capital Research Global Investors, adding an estimated $421M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $337M sold.
- 547 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q4 2023, up from 519 in Q3 2023.
- Funds reported $18B of BioMarin Pharmaceuticals stock for Q4 2023, up 12% quarter-over-quarter.
- 85 funds opened new BioMarin Pharmaceuticals positions in Q4 2023 and 50 closed out, a net change of +35 holders.
- The largest BioMarin Pharmaceuticals buyer in Q4 2023 was Capital Research Global Investors, an estimated $421M added.
- The largest BioMarin Pharmaceuticals seller in Q4 2023 was Baker Bros. Advisors, an estimated $337M sold.
Based on aggregated 13F filings for Q4 2023.